Markets:

Overview

News

Currencies

International

Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

5.455 +0.035 (+0.65%)

Streaming Delayed Price Updated: 3:15 PM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

ARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm

August 20, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action

August 20, 2024

From Robbins LLP

Via Business Wire

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 19, 2024

From The Schall Law Firm

Via Business Wire

What 6 Analyst Ratings Have To Say About Ardelyx ↗

August 02, 2024

Via Benzinga

Analyst Expectations For Ardelyx's Future ↗

June 20, 2024

Via Benzinga

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

August 19, 2024

From Faruqi & Faruqi, LLP

Via Business Wire

Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

August 19, 2024

From The Rosen Law Firm, P.A.

Via Business Wire

Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX

August 18, 2024

From Robbins LLP

Via GlobeNewswire

How Is The Market Feeling About Ardelyx? ↗

June 04, 2024

Via Benzinga

What Analysts Are Saying About Ardelyx Stock ↗

May 24, 2024

Via Benzinga

Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

August 08, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

August 01, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion

July 31, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Get Your Money Out of These 3 Biotech Stocks Before the End of July ↗

July 28, 2024

These stocks are at a risk of providing negative returns to shareholders due to the several operational challenges faced by the companies.

Via InvestorPlace

Ardelyx Files Lawsuit Over Medicare Drug Payment Rules, Claims It Will Limit Patient Access To Kidney Disease Treatment ↗

July 18, 2024

Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug accessibility.

Via Benzinga

Topics Lawsuit

Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

July 18, 2024

Conference call scheduled for 4:30 p.m. Eastern Time

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines

July 17, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Why Ardelyx Stock Is Dropping ↗

July 02, 2024

Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD)...

Via Benzinga

To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA

July 02, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines

June 28, 2024

From Ardelyx, Inc.

Via GlobeNewswire

3 Stocks Under $10 With the Potential to Make You a Millionaire ↗

June 16, 2024

Looking for volume plays? Here are three stocks under $10 that might just drive your earnings to millions in the next few years.

Via InvestorPlace

Ardelyx, Inc. Reports Employment Inducement Grants

May 30, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Medical Moonshots: 3 Biotech Stocks Set to Skyrocket ↗

May 30, 2024

Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended.

Via InvestorPlace

8 Health Care Stocks Whale Activity In Today's Session ↗

May 23, 2024

Via Benzinga

Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

May 22, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

May 21, 2024

From Ardelyx, Inc.

Via GlobeNewswire

The 3 Best Penny Stocks to Buy in May 2024 ↗

May 19, 2024

Ride the momentum with these affordable penny stocks as they continue to display for solid profits this year.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

May 17, 2024

Via Benzinga

Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)

May 16, 2024

From Ardelyx, Inc.

Via GlobeNewswire

7 Cheap Penny Stocks to Buy Now: May 2024 ↗

May 15, 2024

Discover seven penny stocks poised for significant gains in 2024. Explore opportunities in cannabis, mining, EVs, and more.

Via InvestorPlace

Topics Cannabis

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.